Your browser is no longer supported. Please, upgrade your browser.
URGN UroGen Pharma Ltd. daily Stock Chart
URGN [NASD]
UroGen Pharma Ltd.
Index- P/E- EPS (ttm)-6.15 Insider Own0.90% Shs Outstand21.75M Perf Week-6.44%
Market Cap450.69M Forward P/E- EPS next Y-4.61 Insider Trans-2.33% Shs Float19.29M Perf Month10.73%
Income-130.40M PEG- EPS next Q-1.50 Inst Own72.70% Short Float16.51% Perf Quarter-10.32%
Sales0.40M P/S1126.73 EPS this Y-6.70% Inst Trans-0.07% Short Ratio21.09 Perf Half Y-13.41%
Book/sh6.56 P/B3.26 EPS next Y25.20% ROA-68.90% Target Price- Perf Year-1.11%
Cash/sh5.94 P/C3.60 EPS next 5Y- ROE-76.20% 52W Range13.12 - 35.21 Perf YTD-35.96%
Dividend- P/FCF- EPS past 5Y-65.20% ROI- 52W High-39.31% Beta1.68
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin87.10% 52W Low62.90% ATR1.16
Employees186 Current Ratio7.90 Sales Q/Q1966.70% Oper. Margin- RSI (14)49.76 Volatility5.86% 5.31%
OptionableYes Debt/Eq0.00 EPS Q/Q-33.60% Profit Margin- Rel Volume0.36 Prev Close20.47
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume150.95K Price21.37
Recom1.70 SMA201.74% SMA50-0.68% SMA200-11.82% Volume55,072 Change4.40%
Apr-16-20Reiterated H.C. Wainwright Buy $53 → $57
Apr-13-20Reiterated H.C. Wainwright Buy $75 → $53
Jan-09-20Initiated National Securities Neutral $37
May-30-19Initiated JP Morgan Neutral
May-29-19Initiated Goldman Neutral
Jan-29-19Initiated H.C. Wainwright Buy $82
Nov-08-18Resumed Jefferies Buy
Apr-04-18Upgrade Raymond James Mkt Perform → Outperform
Jan-02-18Initiated Ladenburg Thalmann Buy $50
Nov-15-17Reiterated Oppenheimer Outperform $32 → $51
Nov-15-17Downgrade Raymond James Outperform → Mkt Perform
Oct-07-20 12:58PM  
Oct-05-20 08:00AM  
Sep-15-20 12:14PM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Sep-04-20 08:00AM  
Aug-27-20 08:00AM  
Aug-10-20 05:00PM  
08:33AM  
08:00AM  
Aug-03-20 08:00AM  
Jun-15-20 08:43PM  
Jun-05-20 08:00AM  
Jun-01-20 08:00AM  
May-15-20 09:01AM  
09:00AM  
May-09-20 02:31PM  
May-07-20 08:00AM  
May-01-20 08:00AM  
Apr-30-20 09:05AM  
08:00AM  
Apr-21-20 12:34PM  
Apr-16-20 10:37AM  
08:09AM  
Apr-15-20 06:22PM  
Apr-06-20 08:53AM  
Apr-03-20 08:00AM  
Mar-23-20 08:00AM  
Mar-16-20 11:45AM  
Mar-06-20 08:00AM  
Mar-02-20 08:00AM  
Feb-25-20 08:00AM  
Feb-24-20 08:00AM  
Jan-30-20 08:59AM  
Jan-08-20 08:00AM  
Dec-19-19 08:00AM  
Dec-17-19 07:36PM  
Dec-16-19 12:00PM  
Dec-06-19 08:00AM  
Dec-01-19 03:06PM  
Nov-18-19 08:00AM  
Nov-12-19 08:00AM  
07:20AM  
Nov-11-19 08:00AM  
Nov-06-19 10:16AM  
08:00AM  
Sep-30-19 08:00AM  
Sep-24-19 04:01PM  
10:25AM  
Sep-18-19 12:15PM  
Sep-10-19 08:00AM  
Sep-06-19 04:05PM  
Aug-13-19 03:05PM  
Aug-12-19 04:23PM  
Aug-10-19 07:11AM  
Aug-09-19 08:00AM  
Aug-05-19 08:00AM  
Jul-23-19 10:43AM  
Jul-16-19 09:48AM  
Jul-05-19 05:14PM  
Jul-01-19 08:00AM  
May-30-19 08:00AM  
May-26-19 08:18AM  
May-20-19 12:48PM  
May-09-19 01:23PM  
08:00AM  
May-07-19 12:53PM  
May-06-19 11:00AM  
May-05-19 04:25PM  
May-02-19 08:00AM  
Apr-23-19 08:00AM  
Apr-20-19 07:02PM  
Apr-16-19 10:21AM  
Apr-05-19 09:12AM  
Mar-25-19 02:39PM  
Mar-05-19 08:00AM  
Feb-28-19 11:37AM  
08:00AM  
Feb-21-19 08:00AM  
Feb-19-19 08:15AM  
Feb-06-19 12:00PM  
Jan-29-19 02:17PM  
Jan-28-19 04:05PM  
Jan-24-19 12:26PM  
07:45AM  
Jan-23-19 10:16PM  
07:22AM  
Jan-22-19 04:01PM  
Jan-08-19 08:00AM  
Jan-03-19 06:30AM  
Dec-22-18 12:36AM  
Dec-20-18 10:07AM  
Dec-17-18 08:00AM  
Dec-03-18 07:25AM  
Nov-12-18 08:00AM  
Nov-06-18 08:00AM  
Nov-05-18 08:00AM  
Oct-30-18 08:00AM  
Oct-24-18 08:50AM  
Oct-05-18 03:35PM  
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; and Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery. UroGen Pharma Ltd. was founded in 2004 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFREUNDSCHUH PETER P.Chief Financial OfficerOct 15Sale21.772,40052,24810,405Oct 16 03:41 PM
Schoenberg MarkChief Medical OfficerSep 04Sale20.203487,03019,236Sep 08 04:48 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerSep 01Sale22.8250911,6157,888Sep 01 02:37 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerJul 27Sale23.511413,3157,355Jul 28 05:34 PM
Schoenberg MarkChief Medical OfficerJul 27Sale23.51701,64618,543Jul 28 05:32 PM
Schoenberg MarkChief Medical OfficerJun 04Sale27.513499,60218,404Jun 05 02:31 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerMay 20Sale25.073588,9757,079May 20 04:44 PM
Barrett Elizabeth A.Chief Executive OfficerMay 12Option Exercise0.0035,2290157,465May 14 01:07 PM
Schoenberg MarkChief Medical OfficerApr 27Sale24.35701,70517,711Apr 28 01:53 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerApr 27Sale24.351413,4336,396Apr 28 01:51 PM
Mullennix StephenChief Operating OfficerApr 27Sale24.351453,53110,084Apr 28 01:43 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 20Sale29.6836010,6856,120Feb 24 04:53 PM
Mullennix StephenChief Operating OfficerFeb 14Sale28.0461217,1609,812Feb 18 02:33 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerJan 27Sale29.2866719,5304,438Jan 28 05:15 PM
Mullennix StephenChief Operating OfficerJan 27Sale29.2668420,0148,665Jan 28 05:14 PM
Schoenberg MarkChief Medical OfficerJan 27Sale29.153229,3869,177Jan 28 05:10 PM
Barrett Elizabeth A.Chief Executive OfficerJan 03Option Exercise0.00105,6880122,236Jan 07 06:30 PM
Barrett Elizabeth A.Chief Executive OfficerNov 21Buy28.007,530210,84016,548Nov 22 03:34 PM
Barrett Elizabeth A.Chief Executive OfficerNov 20Buy28.007,470209,1609,018Nov 22 01:35 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerNov 20Sale28.4135410,0573,439Nov 22 01:29 PM
Schoenberg MarkChief Medical OfficerNov 19Buy28.171,96055,2137,967Nov 21 08:49 PM
Barrett Elizabeth A.Chief Executive OfficerNov 15Buy26.001,54840,2481,548Nov 18 07:32 PM
Mullennix StephenChief Operating OfficerNov 14Sale26.0060815,8067,683Nov 18 04:04 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.